Michele Bauer
Co-Founder & Partner @ Medicxi
Geneva, Switzerland
Michele Bauer is a Series A investor at Medicxi in Geneva focused on Therapeutics and Biotechnology. Michèle Ollier is the Partner at Index Ventures.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Michele Bauer invests in
Stages Michele Bauer invests in
Countries Michele Bauer invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Therapeutics 2 (67%)
- Biotechnology 2 (67%)
- Medical 1 (33%)
- Health Care 1 (33%)
- Life Science 1 (33%)
Stage
- Series A 1 (33%)
- Series B 1 (33%)
- Venture - Series Unknown 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Palladio Bio is a clinical-stage company developing transformative medicines for orphan diseases of the kidney. The company specializes in the fields of biotechnology, pharmaceutical. and therapeutics. Its products are designed for renal disease, kidney disease, and polycystic kidney disease.The company was founded in 2015 and headquartered inHorsham, Pennsylvania. | $20M / Series B / Sep 25, 2020 | ||
| Diasome Pharmaceuticals is a clinical stage diabetes therapeutics company that designs and develops insulin-based therapies. The company’s products include Oral HVD-I, a targeted oral insulin in a pill or gel cap dose form; HDV-I, an injectable short acting insulin; and HDV-B, an injectable basal long acting insulin. It develops products forpatients suffering from Type 1 and Type 2 diabetes. Diasome Pharmaceuticals was founded in 2004 and is based in Conshohocken, Pennsylvania. | $30M / Venture - Series Unknown / Jul 05, 2017 | ||
| Palladio Bio is a clinical-stage company developing transformative medicines for orphan diseases of the kidney. The company specializes in the fields of biotechnology, pharmaceutical. and therapeutics. Its products are designed for renal disease, kidney disease, and polycystic kidney disease.The company was founded in 2015 and headquartered inHorsham, Pennsylvania. | Series A |
Co-Investors
Black Beret Life Sciences
1 deal together
JDRF T1D Fund
1 deal together
McDonald Partners
1 deal together
OUP (Osage University Partners)
1 deal together
Roche Venture Fund
1 deal together
Samsara BioCapital
1 deal together
About Medicxi
Medicxi is an investment firm that focuses on the life sciences sector. It was established in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.
Medicxi Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Giovanni Pericolini
Finance Director & CFO
|
|||
Kevin Johnson
Co-Founder & Partner
|
|||
Mark Boer
Member of the Board of Advisors
|
|||
|
Michele Bauer
Co-Founder & Partner
|
|||
Trevor Baglin
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Michele Bauer invest in?
Michele Bauer invests primarily in Therapeutics, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Michele Bauer?
Public channels for Michele Bauer include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Michele Bauer last invest?
The most recent investment recorded for Michele Bauer closed in Sep 2020. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
